Benoît Tessoulin

30PUBLICATIONS
117CO-AUTHORS
Haematological tumoursPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Transplantation immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (30)

|Feb 19, 2026
CD40/PI3K/FOXO1 axis rewiring drives microenvironment-dependent BIM silencing to sustain lymphoma growth and survival.

Candice Madiot, Céline Bellanger, Christelle Dousset

|Jan 16, 2026
Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study.

Krish Patel, Julie M Vose, Sunita D Nasta

|Nov 03, 2025
Synthetic control arm from mixed clinical trials and real-world data from the LYSA group for untreated diffuse large B-cell lymphoma patients aged over 80 years: a bona fide strategy for innovative clinical trials.

Valentin Letailleur, Isabelle Chaillol, Fanny Cherblanc

|Oct 22, 2025
Late failure of aggressive B-cell lymphoma after CAR T-cell therapy: a LYSA study from the DESCAR-T registry.

Federico Erbella, Emmanuel Bachy, Guillaume Cartron

|Sep 30, 2025
Outcome of patients with mantle cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T study by LYSA Group.

Marion Aymard, Morgane Cheminant, Roch Houot

|Aug 22, 2025
Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study.

Nirav N Shah, Pier Luigi Zinzani, Michael Wang

Pageof 5

Frequent Collaborators

7 joint publications

Franck Morschhauser

6 joint publications

Yannick Le Bris

6 joint publications

Cyrille Touzeau

6 joint publications

Steven Le Gouill